Rapiscan 400 microgram solution for injection
Sponsors
Synektik S.A., GE Healthcare Limited, Vaestra Goetalandsregionen, Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Conditions
Cardiovascular diseaseCoronary Artery DiseaseCoronary artery chronic total occlusionKawasaki diseasePatients who need to undergo a clinically indicated pharmacologic stress perfusion CMR test and who are considered fit for a pharmacological stress perfusion CMR by the investigator. The pharmacologic stress perfusion CMR may be performed in patients for further evaluation of cardiovascular conditions or diseasesand post-cardiac surgery / transplantationbut not limited tocongenital coronary abnormalities
Phase 1
Phase 2
Phase 3
A Phase III Prospective, Multicenter, Open-label Study to Assess Diagnostic Efficacy of a Novel 18F-labelled Tracer, SYN2, for Positron Emission Tomography in Subjects with Suspected Coronary Artery Disease
RecruitingCTIS2023-506971-89-00
Start: 2024-01-25Target: 220Updated: 2026-01-07
Prognostic Performance of Quantitative Myocardial Perfusion Imaging Using H2[15O] Positron Emission Tomography in Coronary Artery Disease - The AQUA COR trial
Not yet recruitingCTIS2024-518706-41-01
Target: 40000Updated: 2026-06-03